STOCKHOLM--(BUSINESS WIRE)--Regulatory News:
Moberg Pharma AB (OMX:MOB)(STO:MOB) today announced positive interim results from its ongoing phase ll study of MOB-015. After six months of treatment with MOB-015, 40 per cent of the patients were mycologically cured and no safety concerns were identified. MOB-015 is a novel topical formulation of terbinafine for the treatment of nail fungus (onychomycosis).
Help employers find you! Check out all the jobs and post your resume.
